This document provides an overview of Vaccinogen and its cancer vaccine OncoVAX. OncoVAX is designed to reduce the risk of cancer recurrence after surgery and has shown statistically significant results in reducing recurrence in phase 3 trials for stage 2 colon cancer. Vaccinogen has completed 5 clinical studies involving over 750 patients and is in the final stages of clinical development. OncoVAX represents a potential $5 billion market opportunity in the US and Europe for treating colon and other cancers. The manufacturing process for OncoVAX is straightforward and scalable.
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. Key points include:
- Inovio is developing DNA-based immunotherapies to generate T-cell immune responses against cancers and infectious diseases.
- Their lead program, VGX-3100, showed positive Phase II efficacy results in treating HPV-related cervical dysplasia and aims to expand to other HPV-associated cancers.
- Other clinical programs include INO-3112 for cervical cancer, INO-1400 targeting hTERT for various cancers, and INO-1800 for hepatitis B.
- The document discusses attributes of an ideal T-cell generating immunotherapy and how Inovio
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
Inovio is developing powerful DNA-based immunotherapy and vaccine platforms. They have shown clinical proof of concept for treating pre-cancerous conditions and generating antigen-specific CD8+ T cells in vivo. Their lead product VGX-3100 has achieved efficacy endpoints in a phase II cervical dysplasia trial and will enter phase III in 2016. Inovio is pursuing both monotherapy and combination approaches for cancer as well as partnerships with AstraZeneca and others. They have a broad pipeline of products in clinical trials for cancer and infectious diseases.
Global cancer vaccine market & clinical trial insightKuicK Research
The document discusses global cancer vaccine market and clinical trials. It provides an overview of the history and development of cancer vaccines. Currently, there are a range of cancer therapeutics available but they have limitations like low effectiveness and specificity. Researchers have developed cancer vaccines to alleviate patient suffering and they work by activating the immune system to attack cancer cells. There are now numerous cancer vaccines in clinical trials for different cancer types. Several have also been approved and are available commercially. The market for cancer vaccines is growing due to factors like fewer side effects, specificity, and innovations in delivery methods. Many companies are actively investing in developing new cancer vaccines.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
VGX-3100, Inovio's DNA immunotherapy, showed promising results in treating cervical dysplasia in a Phase II clinical trial. The trial met its primary endpoint, with 49.5% of VGX-3100 patients experiencing regression of high-grade cervical lesions to CIN1 or normal tissue, compared to 30.6% of placebo patients. VGX-3100 also met secondary endpoints including clearance of HPV 16 and 18. Additional analysis found the treatment generated HPV-specific T cell responses and CD8 T cells were present in cervical tissue of treated patients. Based on these results, Inovio is expanding trials of VGX-3100 to treat other HPV-associated cancers and moving
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. Their lead product, VGX-3100, met its primary and secondary efficacy endpoints in a Phase II clinical trial for treating cervical dysplasia caused by HPV infection. The trial showed VGX-3100 significantly reduced cervical lesions and cleared HPV infection compared to the placebo. Inovio is also developing DNA vaccines and immunotherapies for HPV-related cancers, hepatitis B, hepatitis C, HIV, Ebola, and others. Their proprietary SynCon® technology allows for optimized antigen design and electroporation enhances antigen expression and immune responses. Inovio aims to be the best-in-class
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. Key points include:
- Inovio is developing DNA-based immunotherapies to generate T-cell immune responses against cancers and infectious diseases.
- Their lead program, VGX-3100, showed positive Phase II efficacy results in treating HPV-related cervical dysplasia and aims to expand to other HPV-associated cancers.
- Other clinical programs include INO-3112 for cervical cancer, INO-1400 targeting hTERT for various cancers, and INO-1800 for hepatitis B.
- The document discusses attributes of an ideal T-cell generating immunotherapy and how Inovio
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
Inovio is developing powerful DNA-based immunotherapy and vaccine platforms. They have shown clinical proof of concept for treating pre-cancerous conditions and generating antigen-specific CD8+ T cells in vivo. Their lead product VGX-3100 has achieved efficacy endpoints in a phase II cervical dysplasia trial and will enter phase III in 2016. Inovio is pursuing both monotherapy and combination approaches for cancer as well as partnerships with AstraZeneca and others. They have a broad pipeline of products in clinical trials for cancer and infectious diseases.
Global cancer vaccine market & clinical trial insightKuicK Research
The document discusses global cancer vaccine market and clinical trials. It provides an overview of the history and development of cancer vaccines. Currently, there are a range of cancer therapeutics available but they have limitations like low effectiveness and specificity. Researchers have developed cancer vaccines to alleviate patient suffering and they work by activating the immune system to attack cancer cells. There are now numerous cancer vaccines in clinical trials for different cancer types. Several have also been approved and are available commercially. The market for cancer vaccines is growing due to factors like fewer side effects, specificity, and innovations in delivery methods. Many companies are actively investing in developing new cancer vaccines.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
VGX-3100, Inovio's DNA immunotherapy, showed promising results in treating cervical dysplasia in a Phase II clinical trial. The trial met its primary endpoint, with 49.5% of VGX-3100 patients experiencing regression of high-grade cervical lesions to CIN1 or normal tissue, compared to 30.6% of placebo patients. VGX-3100 also met secondary endpoints including clearance of HPV 16 and 18. Additional analysis found the treatment generated HPV-specific T cell responses and CD8 T cells were present in cervical tissue of treated patients. Based on these results, Inovio is expanding trials of VGX-3100 to treat other HPV-associated cancers and moving
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. Their lead product, VGX-3100, met its primary and secondary efficacy endpoints in a Phase II clinical trial for treating cervical dysplasia caused by HPV infection. The trial showed VGX-3100 significantly reduced cervical lesions and cleared HPV infection compared to the placebo. Inovio is also developing DNA vaccines and immunotherapies for HPV-related cancers, hepatitis B, hepatitis C, HIV, Ebola, and others. Their proprietary SynCon® technology allows for optimized antigen design and electroporation enhances antigen expression and immune responses. Inovio aims to be the best-in-class
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. They have demonstrated efficacy of their VGX-3100 immunotherapy in a phase II trial for HPV-related cervical dysplasia. Inovio plans to start a phase III trial for VGX-3100 in 2017 and pursue other HPV-related indications. They are also developing immunotherapies for cancers in combination with checkpoint inhibitors, with a phase I/II trial starting in early 2017. In addition, Inovio is developing vaccines for infectious diseases like HIV, Ebola, Zika, and hepatitis B, with phase I data expected in 2017 that could support further development.
1. The document discusses HPV vaccines and their efficacy in preventing cervical cancer. It provides data on HPV prevalence and HPV types that cause cervical cancer in different regions.
2. Clinical trials found that HPV vaccines were over 90% effective in preventing precancerous cervical lesions caused by HPV types 16 and 18. Immunity appears to last for many years.
3. Global licensure of the two available HPV vaccines has expanded rapidly, though affordability remains a challenge for middle-income countries. Efforts are underway to make the vaccines more widely available in developing countries through pricing strategies and GAVI.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
This document provides an overview of Inovio Pharmaceuticals, a company developing DNA-based immunotherapies and vaccines. It summarizes that Inovio is a global leader in active immune therapy, with the best T cell responses shown in clinical studies. It notes that key upcoming value drivers in 2014 include Phase II efficacy data for their lead drug VGX-3100 for cervical dysplasia, and the initiation of multiple new clinical trials for various cancer and infectious disease indications. The document emphasizes Inovio's ability to generate best-in-class T cell responses for immunotherapy using their proprietary DNA delivery technology and development of synthetic vaccines.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
The document summarizes Inovio Pharmaceuticals' immunotherapy platform and development pipeline. Key points include:
1) Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases using its SynCon platform and CELLECTRA delivery device.
2) Its lead product, VGX-3100 for HPV-related diseases, achieved efficacy in a phase II trial and plans to start a phase III trial in 2017.
3) Inovio is also developing immunotherapies for immuno-oncology including combination trials with checkpoint inhibitors starting in 2017.
4) It has infectious disease vaccines in development for Ebola, MERS, Zika
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Vaccine supply crunch adds to risk of covidSABC News
With Africa-bound COVID-19 vaccine doses from the Serum Institute of India delayed for the foreseeable future, slow vaccine rollouts and new variants making inroads, the risk of a new wave of infections in Africa remains high.
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
- Dr. Joseph Kim presented on Inovio's DNA immunotherapy technologies and clinical pipeline.
- Their lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II trial for treating HPV-related cervical dysplasia.
- Inovio is developing immunotherapies targeting HPV-related cancers and diseases, as well as cancers related to hTERT and prostate cancer, using their DNA plasmid vaccine approach coupled with electroporation delivery.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
Dr. Joseph Kim, President & CEO of Inovio Pharmaceuticals, discussed Inovio's progress in developing DNA immunotherapies to treat cancers and infectious diseases. Key highlights included Phase II clinical trial results for VGX-3100 showing it met efficacy endpoints for treating HPV-related cervical dysplasia, additional cancer trials starting in 2014, and the potential for Inovio's therapies to provide non-surgical treatments and preventive vaccines. Inovio is a global leader in active immune therapies and aims to transform the fight against diseases through its SynCon DNA immunotherapy platform.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Abstract—Human papilloma virus (HPV) is the main reason for cervical carcinoma. The viral E7 oncogene induces increasing expression of the cyclin dependent kinase inhibitor p16 INK4a in dysplastic cells. This can be used to identify dysplastic cells in histological slides. The aim of this study was to determine the presence of p16INK4a expression and to evaluate the diagnostic value of p16 immunohistochemical (IHC) investigation in different types of lesions in the uterine cervix. The study was performed on 112 samples of cervical biopsy. All samples were selected from the records of Pathology services in University Hospital-Pleven, Bulgaria. The samples were collected in four separate groups: reactive non dysplastic changes (n=26); different degrees of intraepithelial dysplasia (n=38); invasive squamous cell carcinoma (n=32); endocervical lesions with glandular origin – microglandular hyperplasia, Adenocarcinoma in situ and invasive endocervical adenocarcinoma (n=16). In all samples immunohistochemical analysis using antibodies to p16INK4a was performed. Results. In the cases with dysplastic lesions and invasive carcinomas was found strong correlation between the level of expression of p16INK4a and the level of cervical neoplasia (p<0.01). All 26 cases (100%) of non-dysplastic cervical lesions are negative for p16INK4a. The most cases of CIN III group (14cases-87.5%) showed strong cytoplasmic and nuclear expression of p16INK4a in the whole depth of the epithelium. Strong mainly nuclear overexpression was found in all invasive cervical adenocarcinomas. Conclusions. P16INK4a overexpression is associated to high-grade precancerous lesions and cervical carcinomas. Immunohistochemical evaluation can be useful biomarker in identifying HR-HPV- infected low-grade lesions.
Hangw/ is a global, mobile social media platform that allows users to connect and share live video broadcasts. It has grown rapidly since launch, with over 250,000 downloads and millions of user sessions. The platform generates revenue by showing ads before, during, and after live broadcasts, and shares a portion of ad dollars with broadcasters. Celebrities, athletes, and other influencers use Hangw/ to interact directly with their fans.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. They have demonstrated efficacy of their VGX-3100 immunotherapy in a phase II trial for HPV-related cervical dysplasia. Inovio plans to start a phase III trial for VGX-3100 in 2017 and pursue other HPV-related indications. They are also developing immunotherapies for cancers in combination with checkpoint inhibitors, with a phase I/II trial starting in early 2017. In addition, Inovio is developing vaccines for infectious diseases like HIV, Ebola, Zika, and hepatitis B, with phase I data expected in 2017 that could support further development.
1. The document discusses HPV vaccines and their efficacy in preventing cervical cancer. It provides data on HPV prevalence and HPV types that cause cervical cancer in different regions.
2. Clinical trials found that HPV vaccines were over 90% effective in preventing precancerous cervical lesions caused by HPV types 16 and 18. Immunity appears to last for many years.
3. Global licensure of the two available HPV vaccines has expanded rapidly, though affordability remains a challenge for middle-income countries. Efforts are underway to make the vaccines more widely available in developing countries through pricing strategies and GAVI.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
This document provides an overview of Inovio Pharmaceuticals, a company developing DNA-based immunotherapies and vaccines. It summarizes that Inovio is a global leader in active immune therapy, with the best T cell responses shown in clinical studies. It notes that key upcoming value drivers in 2014 include Phase II efficacy data for their lead drug VGX-3100 for cervical dysplasia, and the initiation of multiple new clinical trials for various cancer and infectious disease indications. The document emphasizes Inovio's ability to generate best-in-class T cell responses for immunotherapy using their proprietary DNA delivery technology and development of synthetic vaccines.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
The document summarizes Inovio Pharmaceuticals' immunotherapy platform and development pipeline. Key points include:
1) Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases using its SynCon platform and CELLECTRA delivery device.
2) Its lead product, VGX-3100 for HPV-related diseases, achieved efficacy in a phase II trial and plans to start a phase III trial in 2017.
3) Inovio is also developing immunotherapies for immuno-oncology including combination trials with checkpoint inhibitors starting in 2017.
4) It has infectious disease vaccines in development for Ebola, MERS, Zika
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
This document provides an overview of Inovio Pharmaceuticals and their DNA immunotherapy technology. Some key points:
- Inovio is developing DNA immunotherapies to generate targeted immune responses to prevent and treat cancers and infectious diseases. Their lead product VGX-3100 is in Phase II trials for HPV-associated precancers.
- Their approach uses optimized synthetic consensus DNA plasmids delivered intramuscularly with electroporation to produce targeted antigen-specific T-cell responses. This has shown best-in-class T cell responses in clinical trials.
- Upcoming milestones include Phase II efficacy data for VGX-3100 in mid-2014, additional cancer vaccine
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Vaccine supply crunch adds to risk of covidSABC News
With Africa-bound COVID-19 vaccine doses from the Serum Institute of India delayed for the foreseeable future, slow vaccine rollouts and new variants making inroads, the risk of a new wave of infections in Africa remains high.
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
- Dr. Joseph Kim presented on Inovio's DNA immunotherapy technologies and clinical pipeline.
- Their lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II trial for treating HPV-related cervical dysplasia.
- Inovio is developing immunotherapies targeting HPV-related cancers and diseases, as well as cancers related to hTERT and prostate cancer, using their DNA plasmid vaccine approach coupled with electroporation delivery.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
Inovio is developing DNA-based immunotherapies and vaccines to treat cancer and infectious diseases. Their lead product VGX-3100 met primary and secondary endpoints in a Phase II cervical dysplasia trial. Inovio has multiple cancer and infectious disease products in development and partnerships with AstraZeneca and Roche worth over $1 billion in potential milestones. They are pursuing DNA-based monoclonal antibody products and have over $100 million in non-dilutive funding supporting their vaccine programs.
Dr. Joseph Kim, President & CEO of Inovio Pharmaceuticals, discussed Inovio's progress in developing DNA immunotherapies to treat cancers and infectious diseases. Key highlights included Phase II clinical trial results for VGX-3100 showing it met efficacy endpoints for treating HPV-related cervical dysplasia, additional cancer trials starting in 2014, and the potential for Inovio's therapies to provide non-surgical treatments and preventive vaccines. Inovio is a global leader in active immune therapies and aims to transform the fight against diseases through its SynCon DNA immunotherapy platform.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
Abstract—Human papilloma virus (HPV) is the main reason for cervical carcinoma. The viral E7 oncogene induces increasing expression of the cyclin dependent kinase inhibitor p16 INK4a in dysplastic cells. This can be used to identify dysplastic cells in histological slides. The aim of this study was to determine the presence of p16INK4a expression and to evaluate the diagnostic value of p16 immunohistochemical (IHC) investigation in different types of lesions in the uterine cervix. The study was performed on 112 samples of cervical biopsy. All samples were selected from the records of Pathology services in University Hospital-Pleven, Bulgaria. The samples were collected in four separate groups: reactive non dysplastic changes (n=26); different degrees of intraepithelial dysplasia (n=38); invasive squamous cell carcinoma (n=32); endocervical lesions with glandular origin – microglandular hyperplasia, Adenocarcinoma in situ and invasive endocervical adenocarcinoma (n=16). In all samples immunohistochemical analysis using antibodies to p16INK4a was performed. Results. In the cases with dysplastic lesions and invasive carcinomas was found strong correlation between the level of expression of p16INK4a and the level of cervical neoplasia (p<0.01). All 26 cases (100%) of non-dysplastic cervical lesions are negative for p16INK4a. The most cases of CIN III group (14cases-87.5%) showed strong cytoplasmic and nuclear expression of p16INK4a in the whole depth of the epithelium. Strong mainly nuclear overexpression was found in all invasive cervical adenocarcinomas. Conclusions. P16INK4a overexpression is associated to high-grade precancerous lesions and cervical carcinomas. Immunohistochemical evaluation can be useful biomarker in identifying HR-HPV- infected low-grade lesions.
Hangw/ is a global, mobile social media platform that allows users to connect and share live video broadcasts. It has grown rapidly since launch, with over 250,000 downloads and millions of user sessions. The platform generates revenue by showing ads before, during, and after live broadcasts, and shares a portion of ad dollars with broadcasters. Celebrities, athletes, and other influencers use Hangw/ to interact directly with their fans.
Exeo Entertainment, Inc. is a manufacturing company concentrating on developing innovative products that fill a clearly defined need in today’s interactive entertainment industry. Featured products include the Zaaz™ smart TV keyboards, Patented Psyko Krypton™ 5.1 gaming headphones, Krankz Bluetooth music headphones, an Android® based portable gaming system, and the Extreme Gamer® -the world’s first multi–disc game changer.
Lattice Inc. provides technology services to correctional facilities and has experienced 700% revenue growth from 2009 to 2013. It offers a suite of cloud-based services that provide secure communications and information technology to smaller facilities. Some of its products and services include video visitation, email, music downloads, and an integrated jail management software solution. While it faces competition from larger national service providers, Lattice has a unique technology advantage in both the US and foreign markets it is expanding into. Its integrated corrections operations network platform provides cost reductions and enhanced revenue streams for facilities.
- Bitcoin Shop is one of the first publicly traded companies focused on the virtual currency ecosystem. It operates an ecommerce platform that accepts bitcoin and other cryptocurrencies as payment.
- The company is developing its BTCS 2.0 platform to expand its product offerings and vendor base. It aims to build a virtual currency ecosystem through ecommerce.
- Bitcoin Shop has a experienced management team with expertise in capital markets, technology, and the virtual currency industry. It plans to grow its customer base and monetize through additional service offerings.
This document contains forward-looking statements and disclaimers about InterCloud's financial projections and business strategies. It notes that actual results could differ from what is presented due to various risk factors. It also states that the pro forma financial information provided is constructed from separate financial statements of the companies involved and does not necessarily represent what the combined financials would be. The document provides an overview of InterCloud, describing its cloud platforms and services, growth strategies, key metrics like revenue and EBITDA, value propositions for investors and customers, examples of professional services case studies, comparative financial statements, and backgrounds of the key executives.
This document discusses Genius Brands International and its business model of providing children's entertainment content across multiple platforms. It notes that animated content has enduring appeal across generations and borders. It highlights Genius Brands' existing properties like Baby Genius which have had success on television and other platforms. The document outlines Genius Brands' plans to expand these properties to new distribution channels internationally and through new merchandise programs. It also presents several new animated series concepts in development. Biographies of the Chairman and CEO Andy Heyward and another executive emphasize their experience in children's entertainment.
The presentation summarizes Clean Coal Technologies' business and technology. It discusses the company's management team and strategic partnerships. It then provides an overview of the growing global demand for coal and issues with existing coal, before detailing CCTI's patented coal upgrading processes. The presentation outlines the technology, its benefits over alternatives, the planned commercial rollout and compelling projected plant economics.
Profire Energy is an oilfield technology company that specializes in burner management systems (BMS). [1] It was founded in 2002 in Alberta, Canada and is now headquartered in Utah with operations throughout North America and Brazil. [2] BMS automate combustion processes, improving safety and efficiency for oil and gas companies by quickly reigniting burner flames when failures occur. [3] While the market for BMS is large due to over 1.3 million oil and gas wells in North America, it remains served by only a few companies. Profire Energy seeks to expand its product offerings and distribution network to capture more of this growing market.
The document discusses accounts payable (AP) transformation and how moving from a paper-based to digital process can provide benefits. It outlines common problems with paper-based AP like high costs and lack of visibility. The solution presented is an end-to-end AP automation platform that handles invoice receipt, approval workflows, payments and spend management. Key benefits highlighted include lower processing costs, improved staff efficiency, and enhanced supplier relationships.
This document discusses Biocept, Inc., a commercial-stage cancer diagnostics company. It provides an overview of Biocept's liquid biopsy platform and tests, including OncoCEE-BR, their first commercialized test for breast cancer. The document also summarizes Biocept's growth strategy, which includes expanding their test menu, improving operational efficiency, and increasing market penetration. It introduces Biocept's executive team and describes their extensive experience in cancer diagnostics, genomics, and life sciences.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
Digiplex is a growing movie theater circuit focused on acquiring and improving theaters. It currently owns 19 theaters with 184 screens across 6 states. Digiplex aims to grow its footprint to 100 theaters and 1,000 screens located primarily in top markets. The company pursues an acquisition strategy of purchasing cash flow positive theaters at reasonable multiples. It also seeks to increase theater utilization and revenue through alternative programming events. Digiplex is led by an experienced management team with deep industry expertise.
Energy Fuels is a uranium mining and milling company with operations in the United States. It currently produces 500,000 pounds of uranium per year and has the goal of increasing production to over 5 million pounds annually as market conditions improve. Energy Fuels owns numerous uranium projects throughout the Western U.S. and operates the only conventional uranium mill in the country. The company is pursuing a strategy of low-cost production while conserving capital and maintaining production optionality for the future.
This document discusses forward-looking statements and risks for Akers Biosciences, Inc. It notes that any statements regarding future financial performance, development of products and services, or opportunities should be considered forward-looking. Actual results may differ due to risks in development, clinical trials, need for capital, and intellectual property maintenance. The document also provides brief biographies of ABI's experienced management team and board.
Oragenics is developing novel antibiotics and probiotics through synthetic biology collaborations. For antibiotics, they are focusing on lantibiotics, a class of naturally produced antibacterial peptides, with a lead compound called MU1140 showing promise against MRSA, VRE and C. difficile. For probiotics, they are engineering bacteria to produce and deliver therapeutics locally for oral diseases. Their OTC probiotic product ProBiora3 supports oral health currently. Upcoming milestones include animal studies on MU1140 in 2014 and generating genetically modified probiotic prototypes in 2014-2015.
Srne sorrento therapeutics-redchip conference presentation (20140123)-reducedRedChip Companies, Inc.
Sorrento Therapeutics presents its next-generation cancer therapeutics pipeline, including Cynviloq and RTX. Cynviloq is a late-stage paclitaxel product that offers potential advantages over Taxol and Abraxane such as higher dosing. It has demonstrated efficacy in multiple Phase 2 trials and is pursuing an abbreviated regulatory pathway for approval. RTX is a clinical stage non-opiate pain treatment that produces long-lasting analgesia through a single injection by targeting TRPV1 receptors. Sorrento aims to develop multiple products from RTX through intrathecal and intraganglionic injections.
Big North Graphite : Presenting at Global Online CEO Conference Small Stocks...RedChip Companies, Inc.
This document provides an overview of Big North Graphite Corp., a mining company exploring graphite opportunities in Mexico and Canada. It summarizes the management team's experience, the capital structure including shares outstanding and warrants, and key investment highlights. Specifically, it notes Big North is currently selling amorphous graphite in Mexico and aims to restart near-term flake graphite production at its recently acquired El Tejon Flake Graphite Mine and Mill in Oaxaca, Mexico, which was previously operational until 2002. A cautionary note also indicates forward-looking statements may materially differ from expectations.
AV Therapeutics is developing new cancer therapeutics including Capridine, a patented drug that has shown specific activity against prostate cancer in preclinical studies. Capridine addresses an unmet need as it has limited side effects and bone toxicity compared to existing treatments. AV Therapeutics plans to submit an IND application to begin Phase I/II clinical trials for Capridine based on its promising preclinical results showing potency against prostate cancer cells and taxane resistant cell lines with no toxicity to bone marrow cells. The company has a strong management team and scientific advisory board from top institutions to advance its pipeline of safer and more effective cancer treatments.
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Company Spotlight
Dr. Joseph Kim, President and CEO of Inovio Pharmaceuticals, discusses Inovio's DNA immunotherapy products and clinical trial progress. Key points include:
1) Inovio's lead product, VGX-3100, met primary and secondary efficacy endpoints in a Phase II cervical dysplasia trial by regressing high-grade lesions and clearing HPV.
2) Phase III development of VGX-3100 for cervical dysplasia is underway, with initiation expected in 2016.
3) Inovio is also developing DNA immunotherapies for HPV-related cancers and expanding VGX-3100's application to additional HPV-associated diseases.
4)
This document summarizes Inovio Pharmaceuticals' DNA immunotherapy platform and development pipeline. Key points include:
- Inovio is developing DNA immunotherapies to activate T cells in vivo to fight cancers and infectious diseases.
- Their platform focuses on designing DNA plasmids that can instruct the body's cells to produce antigens to activate targeted, durable immune responses.
- Their pipeline includes DNA vaccines and immunotherapies for HPV-related cancers and precancers, as well as programs in prostate, lung, breast, pancreatic, and head and neck cancers.
- A phase II trial of VGX-3100 for cervical dysplasia showed significant efficacy and led to a partnership
This document summarizes Inovio Pharmaceuticals' strategy and progress in developing DNA immunotherapies and vaccines to treat cancers and infectious diseases. Key points include:
- Inovio is developing DNA vaccines that activate T cells in vivo to target diseases. Their lead product VGX-3100 achieved efficacy endpoints in a phase II trial for cervical dysplasia.
- They are expanding trials of VGX-3100 to other HPV-related cancers and initiating phase I/IIa trials combining it with IL-12 for cervical cancer and head/neck cancer.
- Other programs include INO-1400 for breast/lung/pancreatic cancer targeting hTERT, INO
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
This document provides an overview of Inovio Pharmaceuticals' DNA immunotherapy platform and clinical programs. It summarizes Inovio's lead product VGX-3100 for treating HPV-related cervical dysplasia and cancers. Phase II clinical trial results showed VGX-3100 significantly reduced cervical lesions and cleared HPV infections compared to placebo. The document discusses Inovio's expansion of HPV programs to other cancers and pre-cancers, as well as clinical trials in head and neck cancer and cervical cancer. It also summarizes Inovio's programs in hepatitis B and telomerase-associated cancers. The document positions Inovio's active DNA immunotherapy approach and T cell-generating platform technology as potentially addressing major
Inovio Pharmaceuticals, Inc. - Corporate PresentationCompany Spotlight
1) Inovio presented data from a phase 2 clinical trial evaluating its DNA immunotherapy VGX-3100 for treating cervical dysplasia. The trial met its primary and secondary endpoints, showing clinically significant efficacy in eliminating high-grade cervical lesions and clearing HPV infection.
2) Inovio is expanding trials of VGX-3100 to treat additional HPV-related cancers and pre-cancers, including cervical cancer, head and neck cancer, and anal cancers. Phase 1/2a trials in cervical cancer and head and neck cancer are underway.
3) Inovio is also developing immunotherapies for other cancers like breast, lung, and pancreatic cancer using a DNA plasmid targeting the hTER
Inovio is developing DNA-based immunotherapies and vaccines to treat cancers and infectious diseases. Their lead product, VGX-3100, met its primary and secondary efficacy endpoints in a Phase II clinical trial for treating cervical dysplasia caused by HPV infection. The trial showed VGX-3100 significantly reduced cervical lesions and cleared HPV infection compared to the placebo. Inovio is also developing DNA vaccines and immunotherapies for HPV-related cancers, hepatitis B, hepatitis C, HIV, Ebola, and others. Their proprietary SynCon® technology allows for optimized antigen design and electroporation enhances antigen expression and immune responses. Inovio aims to be the best-in-class
Inovio is developing DNA immunotherapies to prevent and treat cancers and infectious diseases. Their lead product, VGX-3100, is in Phase II trials for HPV-related cervical dysplasia and has the potential to treat several HPV-related cancers. Inovio uses optimized DNA plasmids delivered through electroporation to generate best-in-class T cell responses against targeted antigens. They have clinical data demonstrating the safety and strong immune responses induced by their approach. Inovio expects Phase II efficacy data for VGX-3100 in mid-2014, which could support advancing to Phase III trials and expanding the use of the product to other HPV-related conditions.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $42 million in non-dilutive funding to support its programs.
Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
This document summarizes Inovio Pharmaceuticals' DNA immunotherapy platform and pipeline. It discusses Inovio's lead product VGX-3100, which demonstrated efficacy in treating HPV-related cervical dysplasia in a Phase II trial. Inovio is expanding VGX-3100 trials to other HPV-related cancers and preparing for Phase III. It also provides updates on Inovio's programs in HPV/cancer, hepatitis B, and cancer targeting hTERT. Inovio is advancing these programs through clinical trials while also developing new DNA immunotherapies and vaccines for additional infectious diseases and cancers.
This document summarizes Inovio Pharmaceuticals' synthetic DNA vaccine technology and development pipeline. The technology is designed to generate robust immune responses, provide universal protection against infectious diseases, and treat cancers. Inovio has multiple vaccine candidates in clinical trials targeting cancers, influenza, HIV, and hepatitis B/C. The company is advancing discussions for partnerships and has received over $35 million in non-dilutive funding to support its programs.
The document discusses Inovio's synthetic vaccine technology, which uses optimized DNA plasmids to generate targeted immune responses without using live or attenuated pathogens. Key points include:
- Inovio is developing synthetic vaccines for cancers, influenza, HIV, and hepatitis B/C using its proprietary SynCon platform and electroporation delivery technology.
- Clinical trials show Inovio's vaccines induce best-in-class immune responses compared to other vaccine technologies.
- The pipeline includes phase 2 vaccines for cervical dysplasia, leukemia, and hepatitis C, with efficacy data expected in 2013.
- The goal is to validate the platform and partner pipeline vaccines while advancing programs with non-dilutive funding.
This randomized controlled trial evaluated the efficacy of topical imiquimod compared to placebo for the treatment of cervical intraepithelial neoplasia grades 2-3 (CIN 2-3). 59 patients with CIN 2-3 were randomly assigned to apply either vaginal suppositories containing 6.25 mg of imiquimod or placebo suppositories for 16 weeks. The main outcome was histologic regression of CIN after treatment. Histologic regression was observed in 73% of patients in the imiquimod group compared to 39% in the placebo group. Complete histologic remission was higher in the imiquimod group (47%) than the placebo group (14%). Topical imiquimod treatment
In this presentation, we discuss the clinical trial process for the new Covid-19 vaccines. We discuss the different vaccine types. We also discuss the Covid-19 vaccines that the UK is currently using in the NHS, as well as vaccines likely to be used in the next year.
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
A Small Biotech/Pharma Company with Great Potentials...Novavax's Conference P...DrMuni Neurophysiologist
Novavax is developing vaccines for two major diseases - RSV and influenza. For RSV, Novavax has a vaccine in Phase 3 clinical trials for maternal immunization that aims to protect newborns. An informational analysis indicated the vaccine is efficacious. An interim analysis is planned for late 2018/early 2019. For influenza, Novavax is developing an adjuvanted nanoparticle vaccine that could improve efficacy, especially in older adults. A Phase 1/2 trial in older adults has been initiated to evaluate the vaccine's safety and immunogenicity compared to existing vaccines.
Presentation Part 2 – Leading with innovationSanofi
Sanofi is building an innovative and diversified vaccine pipeline by expanding into new disease areas and technologies. They have added mRNA and LNP platforms and have 10 new development candidates by 2025, including 6 mRNA vaccines. Sanofi is focusing on first-in-class or best-in-class vaccines and leveraging immunology, antigen design, and the best technology for each target. They are broadening their pipeline to address additional chronic diseases and expanding populations.
This document summarizes the work of Dr. J. Joseph Kim and Inovio Pharmaceuticals to revolutionize vaccines. It discusses Inovio's DNA vaccine technology which uses plasmids and electroporation to efficiently stimulate the immune system. Key points include:
- DNA vaccines can provide universal and therapeutic immune responses against multiple strains of diseases like HPV, cancer, HIV, influenza.
- Clinical trials show DNA vaccines generate best-in-class T-cell and antibody responses.
- The company is developing vaccines for cancers, HPV, HIV, influenza, hepatitis through partnerships and clinical trials.
- A partnership with Roche will develop prostate cancer and hepatitis B vaccines.
This document summarizes Dr. J. Joseph Kim's presentation on revolutionizing vaccines through Inovio's DNA vaccine technology. Some key points:
- Inovio is developing DNA vaccines that use plasmids and electroporation to stimulate the immune system and generate antibody and T-cell immune responses.
- Their vaccines have shown best-in-class immune responses in clinical trials for HPV and HIV.
- Their lead vaccine, VGX-3100 for HPV-related cancers and diseases, is in Phase II trials with efficacy data expected in mid-2014.
- Inovio is targeting major markets for cancers and infectious diseases and collaborating with partners like Roche to develop and commercial
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer currently in a Phase 3 clinical trial. The presentation summarizes the clinical development pipeline, mechanism of action involving T-cell activation, positive safety profile established in previous trials, and potential commercial opportunities. It also briefly discusses the company's pipeline of products targeting other cancers, including GALE-301 and GALE-302 which target Folate Binding Protein in ovarian and endometrial cancers.
Similar to Vgen investor presentation 011814-red chip (20)
“The Coin Tree is a cloud-based storage, insurance, and payment processing platform for bitcoin that leverages cutting edge transactional security to serve the ever expanding virtual currency community."
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment is a theatrical motion picture production and financing company focused on producing and financing edgy, high quality motion pictures with strong cast and lean budgets for a commercial audience.
StarStream Entertainment aims to be a theatrical motion picture production and financing company focused on producing edgy, high quality films with strong casts and lean budgets. It mitigates risk through fiscal precision by financing projects once they are fully developed and ready to produce, offering investors a quicker return. Recent successful films include Lee Daniels' The Butler, Life of Crime, and Life After Beth.
Cancer Genetics provides personalized cancer treatment through molecular diagnostic testing. They have launched 6 proprietary diagnostic products targeting hematological and urogenital cancers. Their tests help determine cancer type and prognosis, guiding treatment selection. Recent acquisitions expand their capabilities and access to new markets in India. Their business model provides clinical testing services to oncologists and biopharma partnerships to support drug development.
InterCloud Systems provides cloud-centric solutions and services to enterprises and service providers. Their two main business focus areas are Software Defined Enterprise and Cloud to Cloud Mobility. They help customers modernize infrastructure, develop cloud strategies, and deliver cloud-centric IT visions aligned to business value. InterCloud partners with major cloud platform and solution providers like VMware, OpenStack, and CloudStack.
This presentation provides an overview of SANUWAVE Health Inc., a regenerative medicine company developing non-invasive biological response activation devices. SANUWAVE's lead product, dermaPACE, is in a Phase III FDA trial for treating diabetic foot ulcers and has the potential for approval in 2015 pending positive results. DermaPACE offers a lower-cost, non-invasive alternative to existing wound therapies. If approved, dermaPACE could address the large diabetic foot ulcer market and be expanded to other applications. SANUWAVE completed a $9.3 million capital raise to fund the dermaPACE trial and has 38 patents covering its shockwave technology platform.
Genius Brands International is a company focused on providing children's entertainment content with purpose for toddlers to tweens. It was created through the merger of A Squared Entertainment and Genius Brands. The document discusses Genius Brands' plans to grow its portfolio of animated properties like Baby Genius, Warren Buffett's Secret Millionaires Club, and new shows in partnership with Stan Lee and Martha Stewart. It aims to distribute this content across television, online, mobile and through a new streaming service, while supporting the content through consumer products licensing. The management team, including Andy and Amy Heyward, have decades of experience in the children's entertainment industry.
StationDigital is a digital media and ecommerce platform that allows users to stream or access any media and purchase digital and physical goods from any device. It has grown rapidly since its public beta launch in 2013, achieving over 1.3 million mobile users. The presentation outlines StationDigital's mission and growth strategy, competitive advantages over other media companies, and large market opportunity in digital media and ecommerce. It argues that StationDigital is well positioned for continued growth and market share capture.
DRONE Aviation Corp (DRNE) was formed in April 2014 to penetrate the rapidly growing Unmanned Aerial Systems (UAS) business in U.S. and abroad for government and commercial customers.
DRNE’s mission is to aggressively penetrate the expanding Drone market with our unique Tethered Drones, which are currently being fielded to the U.S. Department of Defense and State and Local municipalities.
DRNE owns and operates Florida-based Lighter Than Air Systems Corp (LTAS), a developer and supplier of unique and specialized aerial solutions to the U.S. Government, State municipalities, and commercial entities.
InterCloud Systems Incorporated is a single - source provider of end - to - end IT technology and telecom solutions to the ent erprise, service provider, and g overnment markets through “Cloud Platforms” and professional services. “Cloud Comput ing”, is defined as the use of computing resources (compute, NTK, Storage) that are delivered as a managed service over a network. InterCloud offers its service provider custo mers the ability to utilize “cloud” solutions inside their existing network footp rint as well as in a “white label environment” so it can offer a suite of cloud products under their own brand, delivered over the broadband services it presently sell s . ICLD’s cloud services include infrastructure as a service (IaaS), platform as a servi ce (PaaS), and software as a service (SaaS) .
This document provides an overview of Actinium Pharmaceuticals, Inc. and summarizes their proprietary alpha particle immunotherapy technology and product pipeline. Key points include:
1) Actinium has a pipeline of targeted radiotherapy candidates using alpha emitters to treat various blood cancers. Their lead candidate, Iomab-B, is being developed for conditioning blood cancer patients prior to bone marrow transplant.
2) Iomab-B has shown promising results in clinical trials, successfully preparing older refractory AML patients for transplant who otherwise would not be eligible. Actinium has FDA agreement to advance Iomab-B into a Phase III registration trial.
3) Actinium has a proprietary technology
The nuclear energy industry has lain stagnant for over 30 years and has suffered from missteps and perception issues.
Lightbridge is here to innovate and change the conversation. About: Lightbridge is a U.S. nuclear energy company based in McLean, Virginia with operations in Abu Dhabi, Moscow and London. The Company develops proprietary, proliferation resistant, next generation nuclear fuel technologies for current and future nuclear reactor systems. The Company also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. Lightbridge's breakthrough fuel technology is establishing new global standards for safe and clean nuclear power and leading the way to a sustainable energy future. Lightbridge consultants provide integrated strategic advice and expertise across a range of disciplines including regulatory affairs, nuclear reactor procurement and deployment, reactor and fuel technology and international relations. The Company leverages those broad and integrated capabilities by offering its services to commercial entities and governments with a need to establish or expand nuclear industry capabilities and infrastructure.
Richfield Oil & Gas Company (OTCQX: ROIL) is an independent exploration and production company headquartered in Salt Lake City, Utah. The Company’s current oil production flows from wells in fields located in Kansas and Wyoming. In addition to several thousand acres in Kansas, Richfield also owns strategically-located exploratory leases in central Utah on trend to major oil discoveries.
NeoStem, Inc. (“NeoStem” or the “Company”), a biopharmaceutical company, is capitalizing on the paradigm shift occurring in medicine by engaging in the development and manufacture of cellular therapies for oncology, immunology, and regenerative medicines in the United States. The Company anticipates that cell therapy will play a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
American Water provides water and wastewater services to approximately 14 million people in 16 states, has a market capitalization of $8.6 billion, and seeks to continue growing its regulated water business through capital investments and acquisitions while also expanding its complementary market-based business lines. The company has delivered strong total shareholder returns since its 2008 IPO and maintains a transparent dividend policy aimed at increasing its dividend in line with normalized earnings per share growth.
Direct Insite (“DIRI”) provides cloud-based, ERP-agnostic solutions that automate Accounts Payable (AP) and Accounts Receivable (AR) invoice processes for Global 3000 companies. Their solutions include invoice validation, order matching, consolidation, dispute handling and e-payment processing. DIRI helps clients eliminate manual processes and costs associated with doing everything on paper. By migrating from paper to electronic, DIRI can reduce transactions costs 50-70% and reduce time by 80%. Current clients include Siemens, HP, IBM, Saint-Gobain, Shell Oil, and Hyatt with a Global vendor network of 350,000+ suppliers.
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost - effective solutions for the Company’s global customers. The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased techno logy equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead
Quadrant 4 Systems Corporation is a leading provider in of health exchange platforms, innovative software products and proprietary SMAC (social media, mobility, analytics and cloud computing) solutions to enterprise clients in Retail and Manufacturing, Media and Publishing, Financial Services and Health Care sectors.
Energy Fuels is the nation's leading conventional uranium producer, supplying approximately 25% of the uranium produced in the U.S. (based on FY-2013 deliveries). The Company also has the capability to be a significant producer of vanadium. Energy Fuels owns and operates the White Mesa Mill, which is the only conventional uranium mill currently operating in the U.S. The mill is capable of processing 2,000 tons per day of uranium ore and producing up to 8 million lbs. of U3O8 per year (depending on ore grade).
How to Implement a Strategy: Transform Your Strategy with BSC Designer's Comp...Aleksey Savkin
The Strategy Implementation System offers a structured approach to translating stakeholder needs into actionable strategies using high-level and low-level scorecards. It involves stakeholder analysis, strategy decomposition, adoption of strategic frameworks like Balanced Scorecard or OKR, and alignment of goals, initiatives, and KPIs.
Key Components:
- Stakeholder Analysis
- Strategy Decomposition
- Adoption of Business Frameworks
- Goal Setting
- Initiatives and Action Plans
- KPIs and Performance Metrics
- Learning and Adaptation
- Alignment and Cascading of Scorecards
Benefits:
- Systematic strategy formulation and execution.
- Framework flexibility and automation.
- Enhanced alignment and strategic focus across the organization.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
Starting a business is like embarking on an unpredictable adventure. It’s a journey filled with highs and lows, victories and defeats. But what if I told you that those setbacks and failures could be the very stepping stones that lead you to fortune? Let’s explore how resilience, adaptability, and strategic thinking can transform adversity into opportunity.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
Digital Marketing with a Focus on Sustainabilitysssourabhsharma
Digital Marketing best practices including influencer marketing, content creators, and omnichannel marketing for Sustainable Brands at the Sustainable Cosmetics Summit 2024 in New York
Brian Fitzsimmons on the Business Strategy and Content Flywheel of Barstool S...Neil Horowitz
On episode 272 of the Digital and Social Media Sports Podcast, Neil chatted with Brian Fitzsimmons, Director of Licensing and Business Development for Barstool Sports.
What follows is a collection of snippets from the podcast. To hear the full interview and more, check out the podcast on all podcast platforms and at www.dsmsports.net
Part 2 Deep Dive: Navigating the 2024 Slowdownjeffkluth1
Introduction
The global retail industry has weathered numerous storms, with the financial crisis of 2008 serving as a poignant reminder of the sector's resilience and adaptability. However, as we navigate the complex landscape of 2024, retailers face a unique set of challenges that demand innovative strategies and a fundamental shift in mindset. This white paper contrasts the impact of the 2008 recession on the retail sector with the current headwinds retailers are grappling with, while offering a comprehensive roadmap for success in this new paradigm.
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This PowerPoint compilation offers a comprehensive overview of 20 leading innovation management frameworks and methodologies, selected for their broad applicability across various industries and organizational contexts. These frameworks are valuable resources for a wide range of users, including business professionals, educators, and consultants.
Each framework is presented with visually engaging diagrams and templates, ensuring the content is both informative and appealing. While this compilation is thorough, please note that the slides are intended as supplementary resources and may not be sufficient for standalone instructional purposes.
This compilation is ideal for anyone looking to enhance their understanding of innovation management and drive meaningful change within their organization. Whether you aim to improve product development processes, enhance customer experiences, or drive digital transformation, these frameworks offer valuable insights and tools to help you achieve your goals.
INCLUDED FRAMEWORKS/MODELS:
1. Stanford’s Design Thinking
2. IDEO’s Human-Centered Design
3. Strategyzer’s Business Model Innovation
4. Lean Startup Methodology
5. Agile Innovation Framework
6. Doblin’s Ten Types of Innovation
7. McKinsey’s Three Horizons of Growth
8. Customer Journey Map
9. Christensen’s Disruptive Innovation Theory
10. Blue Ocean Strategy
11. Strategyn’s Jobs-To-Be-Done (JTBD) Framework with Job Map
12. Design Sprint Framework
13. The Double Diamond
14. Lean Six Sigma DMAIC
15. TRIZ Problem-Solving Framework
16. Edward de Bono’s Six Thinking Hats
17. Stage-Gate Model
18. Toyota’s Six Steps of Kaizen
19. Microsoft’s Digital Transformation Framework
20. Design for Six Sigma (DFSS)
To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations
Best Competitive Marble Pricing in Dubai - ☎ 9928909666Stone Art Hub
Stone Art Hub offers the best competitive Marble Pricing in Dubai, ensuring affordability without compromising quality. With a wide range of exquisite marble options to choose from, you can enhance your spaces with elegance and sophistication. For inquiries or orders, contact us at ☎ 9928909666. Experience luxury at unbeatable prices.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Unveiling the Dynamic Personalities, Key Dates, and Horoscope Insights: Gemin...my Pandit
Explore the fascinating world of the Gemini Zodiac Sign. Discover the unique personality traits, key dates, and horoscope insights of Gemini individuals. Learn how their sociable, communicative nature and boundless curiosity make them the dynamic explorers of the zodiac. Dive into the duality of the Gemini sign and understand their intellectual and adventurous spirit.
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Tastemy Pandit
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Taste
Vgen investor presentation 011814-red chip
1. First
Quarter
2014
VACCINOGEN
-‐
A
$5+
BILLION
CANCER
VACCINE
OPPORTUNITY
Q1
2014
Stock
Symbol:
VGEN
1
2. Vaccinogen
and
OncoVAX®
A
cancer
vaccine
company
in
its
final
stages
of
clinical
development
with
a
patented
phase
III
asset
-‐
OncoVAX
Stock
symbol
is
VGEN
Q1
2014
Stock
Symbol:
VGEN
2
3. OncoVAX®
• Cancer
vaccine
• Designed
to
reduce
the
risk
of
recurrence
of
cancer
aLer
surgery
• Uses
the
paNent’s
own
tumor
as
vaccine
source
Q1
2014
Stock
Symbol:
VGEN
3
4. Value
ProposiDon
Late
stage
-‐
5
clinical
studies,
including
a
staNsNcally
significant
phase
3
trial
$14
billion
global
market
$5
billion
in
US
&
Europe
Solid
patent
protecNon
to
2025
RelaNvely
simple
logisNcs
with
few
variables
Pursuing
an
untapped
market
with
colon
cancer
BeauNfully
addresses
“heterogeneity
of
cancer”
Q1
2014
Stock
Symbol:
VGEN
4
5. OncoVAX® - Clinical II(a)
C
OncoVAX®
–
Phase
IResultslinical
Results
8701 Study - Recurrence-Free Survival* in Stage II Patients
C u m u l a t i v e
P r o b a b i l i t y
8701
Study
-‐
Recurrence-‐Free
Survival*
in
Stage
II
PaNents
100
90
80
70
Recurrence-Free Survival
(No. of Recurrences or Deaths)
Population
Control
5-year
OncoVAX® p-value
50
All Patients
49 (38.9%)
N=126
39 (30.5%)
N=128
0.073
40
Stage II
(Intent-to-Treat)
29 (37.7%)
N=77
17 (21.3%)
N=80
0.008
Stage II (Treatment 29(37.7%)
Compliant)
N=77
12 (19.4%)
N=62
0.012
30
60
0
1
2
3
4
5
6
7
8
9
10
11
Y e a r s
Treatment
Control
OncoVAX
* This published, randomized Phase IIIa clinical trial was stratified by tumor stage so that a legitimate analysis by tumor stage could be calculated.
These results are for Stage II colon cancer. Some benefit was seen in Stage III colon cancer however the results were not statistically significant.
This study was accepted by the FDA as supportive data for the next Phase IIIb clinical trial to be conducted under an FDA granted SPA with fast
track designation. The Disease-free Survival clinical endpoint will be used for the interim analysis, which is an accepted basis for FDA approval.
The
results
were
published
in
the
BriNsh
Medical
Journal
The
Lancet
January
30,
1999;
353:
345-‐350
Q1
2014
Stock
Symbol:
VGEN
5
6. OncoVAX®
–
Phase
Itage
II
PaNents
linical
Results
II(a)
C
OncoVAX® - Clinical
8701
Study
-‐
Recurrence-‐Free
Interval
(RFI)
in
S Results
C u m u l a t i v e
P r o b a b i l i t y
8701 Study - Recurrence-Free Interval (RFI) in Stage II Patients
100
90
Difference between treated and control 16.1%
80
70
60
0
1
2
3
4
5
6
7
8
9
10
11
Y e a r s
Treatment
Control
O n c o VA X
Date run: 30NOV00
Greatest difference between treated and control in RFI at 18 months post Vx
Greatest
difference
between
treated
and
control
in
RFI
at
18
months
post
Vx
Q1
2014
Stock
Symbol:
VGEN
6
7. Clinical
history
&
foundaDon
for
OncoVAX®
• 751
paNents
treated
over
five
studies
• Phase
III
trial
showed
61%
improvement
of
survival
• Non
treated
group
–
1/3
of
paNents
recurred
(as
stage
4)
• OncoVAX
treated
group
–
only
1/10
recurred
Q1
2014
Stock
Symbol:
VGEN
7
8. Target
market
IniDal
targets
Annual
cases
in
Western
markets
Stage
II
colon
cancer
160,000
Stage
III
colon
cancer
150,000
310,000
total
cases
of
stage
II
&
III
colon
cancer
in
Western
world
Q1
2014
Stock
Symbol:
VGEN
8
9. Key
consideraDons
Item
Key
benefits
Acceptable
price
per
vaccine
$54,000
-‐
$70,000
Internal
cost
per
vaccine
$7,000
-‐
$8,000
US
&
Europe
market
-‐
stage
2
&
stage
3
300,000
cases
per
year
colon
cancer
Likely
market
penetraNon
30%
to
55%
Asian
colon
cancer
market
potenNal
200,000
cases
per
year
Other
potenNal
targets
Renal
cancer,
melanoma,
ovarian
cancer,
non
small-‐cell
lung
cancer
Scale?
Yes
–
all
process
are
the
same
across
all
indicaNons
Q1
2014
Stock
Symbol:
VGEN
9
11. Patent
coverage
• Sterility
Patent
–
covers
the
sterile
manufacturing
process
– Expires
2025
– Approved
in
all
major
markets
• Two
other
patents
being
filed
currently
Q1
2014
Stock
Symbol:
VGEN
11
12. Vaccine
Manufacturing
After injection:
Immune responds by killing
all leftover live tumor cells
3 part process
Step
1
Step
2
Step
3
• 3
grams
of
live
tumor
cells
removed
at
surgery
and
shipped
to
VGEN
• VGEN
makes
cells
into
a
sterile,
“safe
vaccine
–
OncoVAX”
• 30-‐35
days
later,
VGEN
ships
OncoVAX
back
to
the
hospital
for
final
compounding
and
injecNon
PaNent’s
own
tumor
cells
re-‐
injected
4
Nmes
in
the
skin
Q1
2014
On
the
3rd
and
4th
injecNon,
the
immune
system
reacts!
Stock
Symbol:
VGEN
12
13. LogisDcs
=
How
we
“de-‐risk”
this
investment
Vaccine
Material
PaDent’s
own
tumor
Transport
of
Nssue
to
VGEN
Hands
on
manufacturing
Nme
Via
transplant
courier
6
hours
Transport
of
finished
vaccine
AdministraNon
of
vaccine
Internal
costs
per
vaccine
Frozen
via
Fed
Ex
Intradermal
injecNon
$7,000
to
$8,000
Q1
2014
Stock
Symbol:
VGEN
13
14. Colon
Cancer
today
–
sDll
an
untapped
market
Stage
II
colon
cancer
Stage
III
colon
cancer
%
of
all
colon
cancers
40%
37%
Current
treatment
Surgery
only
Surgery
+
chemotherapy
Recurrence
rate
1/3
1/2
Survival
rate
if
cancer
returns
<6%
(now
stage
4)
<6%
(now
stage
4)
Q1
2014
Stock
Symbol:
VGEN
14
16. Coming
up
-‐
Pivotal,
Confirmatory
Phase
III
(b)
• 550
paNent
phase
III
trial
–
confirmatory
– SPA
and
Fast
Track
• Parallel
phase
I/II
study
for
stage
III
colon
cancer
Q1
2014
Stock
Symbol:
VGEN
16
17. Management
Michael
G.
Hanna
Jr.,
Ph.D.
Andrew
L.
Tussing
President
COO
Debra
Hoopes
Chief
Financial
Adviser
John
Powers
OperaNons
-‐
LogisNcs
Dinand
Van
der
Linde
Head
of
Europe
Herbert
C.
Hoover,
MD
Q1
2014
CEO,
Chairman
inventor
Chief
Medical
Adviser
Stock
Symbol:
VGEN
17
18. Medical
Advisory
Board
Michael
G.
Hanna,
Jr.,
Ph.D.
Immunology
John
S.
Macdonald,
MD
Specialist
in
Harvard,
B.
Israel,
Georgetown,
GastrointesNnal
Cancer
New
York
Medical.
College
Benjamin
S.
Carson,
MD
Neurosurgery
Johns
Hopkins,
PresidenNal
Medal
of
Freedom,
authored
100+
publicaNons,
4
books
H.C.
Hoover,
MD
Surgical
Oncology
Johns
Hopkins,
Harvard,
inolved
in
all
5
OncoVAX
studies
Jan
Vermorken,
MD,
Ph.D.
Oncology
University
of
Antwerp,
Vrije,
principal
invesNgator
in
previous
8701
phase
III
OncoVAX
trial
Q1
2014
Stock
Symbol:
VGEN
Invent
of
OncoVAX®
NaNonal
Cancer
InsNtute,
authored
225
publicaNons
18
19. Summary
–
De-‐risking
aspects
of
this
investment
•
•
•
•
•
•
Public
company
–
fully
reporNng
Phase
III
results
in
hand
LogisNcs
–
proven,
stable
and
scalable
Clear
path
ahead
in
colon
cancer
ShiLing
standard
of
care
from
surgery
alone
85%
margins
on
a
mulN-‐billion
market
Q1
2014
Stock
Symbol:
VGEN
19
20. Contact:
• Andrew
L.
Tussing,
President
&
COO
• atussing@vaccinogeninc.com
• (US)
301
668-‐8400
Q1
2014
Stock
Symbol:
VGEN
20
21. Forward
Looking
Statements
This
presentaNon
and
related
commentary
may
contain
forward-‐looking
statements
within
the
meaning
of
the
SecuriNes
Act
of
1933
(the
“Securi(es
Act”)
and
the
SecuriNes
Exchange
Act
of
1934
(the
“Exchange
Act”)
and
are
subject
to
the
safe
harbor
created
by
the
Private
SecuriNes
LiNgaNon
Reform
Act
of
1995.
Vaccinogen
has
based
these
forward-‐looking
statements
largely
on
our
expectaNons
and
projecNons
about
future
events
and
financial
trends
affecNng
the
financial
condiNon
and/or
operaNng
results
of
its
business.
Forward-‐looking
statements
involve
risks
and
uncertainNes;
parNcularly
those
risks
and
uncertainNes
inherent
in
the
process
of
discovering,
developing
and
commercializing
drugs
that
are
safe
and
effecNve
for
use
as
human
therapeuNcs.
There
are
important
factors
that
could
cause
actual
results
to
be
substanNally
different
from
the
results
expressed
or
implied
by
these
forward-‐looking
statements,
including,
among
other
things:
• Vaccinogen’s
ability
to
successfully
manufacture
OncoVAX®
and
other
product
candidates
in
necessary
quanNNes
with
required
quality;
• Vaccinogen’s
ability
to
successfully
obtain
regulatory
approvals
and
commercialize
its
products
that
are
under
development
and
develop
the
infrastructure
necessary
to
support
commercializaNon
if
regulatory
approvals
are
received;
• Vaccinogen’sability
to
complete
and
achieve
posiNve
results
in
ongoing
and
new
clinical
trials;
• Vaccinogen’s
dependence
on
single-‐source
vendors
for
some
of
the
components
used
in
its
product
candidates;
• the
extent
to
which
the
costs
of
any
products
that
Vaccinogen
is
able
to
commercialize
will
be
reimbursable
by
third-‐party
payers;
• the
extent
to
which
any
products
that
we
are
able
to
commercialize
will
be
accepted
by
the
market;
• Vaccinogen’s
dependence
on
our
intellectual
property
and
ability
to
protect
its
proprietary
rights
and
operate
its
business
without
conflicNng
with
the
rights
of
others;
• the
effect
that
any
intellectual
property
liNgaNon,
or
product
liability
claims
may
have
on
Vaccinogen’s
business
and
operaNng
and
financial
performance;
• Vaccinogen’s
expectaNons
and
esNmates
concerning
its
future
operaNng
and
financial
performance;
• the
impact
of
compeNNon
and
regulatory
requirements
and
technological
change
on
Vaccinogen’sbusiness;
• Vaccinogen’s
ability
to
recruit
and
retain
key
personnel;
• Vaccinogen’s
ability
to
enter
into
future
collaboraNon
agreements;
and
• anNcipated
trends
in
our
business
and
the
biotechnology
industry
generally
In
addiNon,
in
this
presentaNon
and
related
commentary,
the
words
“believe,”
“may,”
“will,”
“esNmate,”
“conNnue,”
“anNcipate,”
“intend,”
“plan,”
“expect,”
“potenNal,”
or
“opportunity,”
the
negaNve
of
these
words
or
similar
expressions,
as
they
relate
to
Vaccinogen,
its
business,
future
financial
or
operaNng
performance
or
Vaccinogen’s
management,
are
intended
to
idenNfy
forward-‐looking
statements.
Past
financial
or
operaNng
performance
is
not
necessarily
a
reliable
indicator
of
future
performance
and
you
should
not
use
Vaccinogen’s
historical
performance
to
anNcipate
results
or
future
period
trends.
Because
such
statements
involve
risks
and
uncertainNes,
many
of
which
are
outside
of
Vaccinogen’s
control,
Vaccinogen's
actual
results
and
performance
may
differ
materially
from
the
results
expressed
or
implied
by
such
forward-‐looking
statements.
Given
these
risks
and
uncertainNes,
readers
are
cauNoned
not
to
place
undue
reliance
on
such
forward-‐looking
statements.
Other
important
risk
factors
that
may
affect
Vaccinogen's
business,
results
of
operaNons
and
financial
posiNon
are
discussed
in
its
most
recently
filed
RegistraNon
Statement
on
Form
10
and
in
other
SecuriNes
and
Exchange
Commission
filings.
Unless
otherwise
required
by
law,
Vaccinogen
also
disclaims
any
obligaNon
to
update
its
view
of
any
such
risks
or
uncertainNes
or
to
announce
publicly
the
result
of
any
revisions
to
the
forward-‐looking
statements
made
here.
However,
readers
should
review
carefully
reports
and
documents
that
Vaccinogen
files
periodically
with
the
SecuriNes
and
Exchange
Commission.
Q1
2014
Stock
Symbol:
VGEN
21